| We advocate on behalf of patients with mutual health insurance funds. | 医学研究
> 医学研究 | 监管合作伙伴关系
> 与监管机构合作 | 100 | National | Rarely | 115057856231 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 神经退行性
> 亨廷顿病 | 监管合作伙伴关系
> 与监管机构合作 | Do not know | International | Sometimes | 119075658991 |
| Drug Reimbursement Committee [Commissie Terugbetaling Geneesmiddelen – Drug Reimbursement Committee] via VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform]. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | Regional | Sometimes | 114996669704 |
| Providing information to the organisation that represents us in CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Board] reimbursement consultations concerning a new medicine. | 患者教育
> 患者信息 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | Regional | Sometimes | 115028426381 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 血液
> 镰状细胞病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Rarely | 115028443749 |
| FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products], KCE [Federaal Kenniscentrum voor de Gezondheidszorg – Belgian Health Care Knowledge Centre], and RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]/CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee]. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | Regional | Sometimes | 115034595480 |
| Completed several CTG [Commissie Toekenning Geneesmiddelen – Medicine Allocation Committee] dossiers. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 115036954847 |
| Input from the patient organisation on reimbursement dossiers for new medications (via an extensive questionnaire). | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | Regional | Sometimes | 115039053506 |
| Expert assessments in support of drug reimbursement decisions. | 神经退行性
> 痴呆症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | Regional | Sometimes | 115043013133 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform] and, on occasion, in response to questionnaires issued by RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]. | 过敏
> 哮喘、过敏、特应性皮炎、湿疹 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Sometimes | 115043032741 |
| Advisory board of RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance] in connection with applications for reimbursement modalities for new medicines. | 出血
> 出血性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Rarely | 115049435993 |
| We participate in stakeholder engagement sessions organised by Pharma.be and FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products]. | 血液
> 血液疾病：免疫性血小板减少症（ITP） | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | National | Sometimes | 115021567311 |
| FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products], KCE [Federaal Kenniscentrum voor de Gezondheidszorg – Belgian Health Care Knowledge Centre], and RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance]/CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee]. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | We do not communicate with patients directly | Regional | Sometimes | 115034595480 |
| INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance], Minister of Health. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 115043127768 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 免疫
> 免疫功能低下 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | Over 100,000 | International | Regularly | 119074504996 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 神经退行性
> 亨廷顿病 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | Do not know | International | Sometimes | 119075658991 |
| Drug Reimbursement Committee [Commissie Terugbetaling Geneesmiddelen – Drug Reimbursement Committee] via VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform]. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 10,000 | Regional | Sometimes | 114996669704 |
| Via the VPP [Vlaams Patiënten Platform – Flemish Patients' Platform] on behalf of Alnylam Pharmaceuticals. | 神经退行性
> 淀粉样变性 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | National | Sometimes | 114996917912 |
| In its newsletter No. 71 of November 2024, BCC [Belgian Brain Council - Conseil Belge du Cerveau] expressed its support for the statement issued by the Alzheimer Europe association in response to the EMA [European Medicines Agency]'s refusal to grant a marketing authorisation for Leqembi (lecanemab) for the treatment of mild cognitive impairment (memory and thinking disorders). | 心理健康
> 心理健康：大多数状况 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | International | Sometimes | 115006691079 |
| Providing information to the organisation that represents us in CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Board] reimbursement consultations concerning a new medicine. | 患者教育
> 患者信息 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | Regional | Sometimes | 115028426381 |
| By being a member of umbrella organisations. | 风湿性
> 硬皮病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Sometimes | 115033503861 |
| By being a member of umbrella organisations. | 风湿性
> 硬皮病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Sometimes | 115033503861 |
| Via VPP [Vlaams Patiëntenplatform – Flemish Patients' Platform]. | 癌症
> 癌症：罕见 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Regional | Rarely | 115043019020 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform]. | 过敏
> 哮喘、过敏、特应性皮炎、湿疹 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | Do not know | National | Sometimes | 115043032741 |
| We provide advisory input through VPP [Vlaams Patiëntenplatform – Flemish Patient Platform]. | 过敏
> 哮喘、过敏、特应性皮炎、湿疹 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | Do not know | National | Sometimes | 115043032741 |
| Through our association OntmoetPijn, we are members of the Vlaamse Pijnliga [Flemish Pain League] and use that platform to advocate on behalf of people living with chronic pain. | 神经系统
> 疼痛 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Regional | Sometimes | 115046494165 |
| We are a member of VPP [Vlaams Patiëntenplatform – Flemish Patients' Platform]. They advocate on our behalf. | 神经肌肉
> 神经肌肉疾病：大多数类型 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | Regional | No | 115055397447 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 免疫
> 免疫功能低下 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | Over 100,000 | International | Regularly | 119074504996 |
| Affiliated with the Vlaams Patiëntenplatform [Flemish Patients' Platform] and Kom op Tegen Kanker [Stand Up to Cancer]. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | Regional | Rarely | 115020713219 |
| Advisory board member at Kom op tegen Kanker [Kom op tegen Kanker – Fight Against Cancer]. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | Regional | Rarely | 115036847346 |
| Providing advisory input on legislative work concerning involuntary psychiatric admissions [Belgium]. | 心理健康
> 心理健康：照护者、家人、朋友 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | Regional | Regularly | 115056630689 |
| Regional discussion on the cardiovascular prevention plan, with outreach to municipalities and CPAS [Centre Public d'Action Sociale – Public Centre for Social Welfare]. | 心血管
> 心血管：大多数类型 | 影响政策和立法
> 参与公众听证会和咨询 | 100,000 | National | Regularly | 115042996911 |
| Roundtable discussions in parliament and visits to ministers’ offices. | 癌症
> 癌症：妇科 | 影响政策和立法
> 参与公众听证会和咨询 | 1,000 | National | Rarely | 115045208576 |
| EMA [European Medicines Agency] PCWP [Patients' and Consumers' Working Party] Forum at EU Parliament activities in our members' countries. | 免疫
> 免疫功能低下 | 影响政策和立法
> 参与公众听证会和咨询 | Over 100,000 | International | Regularly | 119074504996 |
| Hearing before the Belgian Senate – 24 November 2023. | 血液
> 镰状细胞病 | 影响政策和立法
> 动员议员和政治领导人 | Do not know | National | Sometimes | 115035784218 |
| Providing advisory input on legislative work concerning involuntary psychiatric admissions. | 心理健康
> 心理健康：照护者、家人、朋友 | 影响政策和立法
> 倡导患者保护法案和权利 | 1,000 | Regional | Regularly | 115056630689 |
| In its newsletter No. 71 of November 2024, BCC [Belgian Brain Council - Conseil Belge du Cerveau] expressed its support for the statement issued by the Alzheimer Europe association in response to the EMA [European Medicines Agency]'s refusal to grant a marketing authorisation for Leqembi (lecanemab) for the treatment of mild cognitive impairment (memory and thinking disorders). | 心理健康
> 心理健康：大多数状况 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 1,000 | International | Sometimes | 115006691079 |
| A legislative anomaly exists with regard to the funding of self-catheterisation for individuals residing in a residential care facility. | 神经系统
> 多发性硬化症 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 5,000 | Regional | Rarely | 115028407747 |
| … certain medications are reimbursed for women with breast cancer but not for men with the same condition. | 癌症
> 癌症（男性）：乳腺 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 100 | Regional | Sometimes | 115031895194 |
| We are calling for improved reimbursement of our medications. | 胃肠道
> IBD | 定价与可负担性倡导
> 倡导公平的药品定价 | 100,000 | Regional | Sometimes | 115020038862 |
| Ensuring reimbursement for specific medicines. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | Regional | Sometimes | 115029939063 |
| Through our association OntmoetPijn, we are a member of the Flemish Pain League, where we actively advocate on behalf of people living with chronic pain — including, for example, issues relating to the cost of medication. | 神经系统
> 疼痛 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100 | Regional | Sometimes | 115046494165 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 肾脏
> 肾脏疾病 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100 | Regional | Sometimes | 115055534359 |
| Request for medication reimbursement. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | Regional | Sometimes | 115057073683 |
| Completing the RIZIV [Rijksinstituut voor ziekte- en invaliditeitsverzekering – National Institute for Health and Disability Insurance] questionnaire in order to obtain reimbursement for medicines. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 5,000 | Regional | Sometimes | 114997831407 |
| An intervention was made in 2015 through the mutual health insurers at INAMI [Institut national d'assurance maladie-invalidité – National Institute for Health and Disability Insurance] to amend the reimbursement conditions for Imitrex SC [subcutaneous injection - used to quickly treat acute migraine attacks and cluster headaches in adults]. | 神经系统
> 偏头痛 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100 | National | Rarely | 115006822909 |
| Reimbursement applications for certain medicines through INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 风湿性
> 狼疮 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100 | National | Regularly | 115029783188 |
| Advisory board of RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance] in connection with applications for reimbursement modalities for new medicines. | 出血
> 出血性疾病：大多数类型 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 5,000 | National | Rarely | 115049435993 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster [atient participation cluster within a Flemish primary-care network]. | 肾脏
> 肾脏疾病 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100 | Regional | Sometimes | 115055534359 |
| Recommendation submitted to the CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee] via a completed questionnaire: reimbursement of Buccolam for individuals with epilepsy aged 18 years and over. | 神经系统
> 癫痫 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 1,000 | Regional | Sometimes | 115057861541 |
| Completing the RIZIV [Rijksinstituut voor ziekte- en invaliditeitsverzekering – National Institute for Health and Disability Insurance] questionnaire in order to obtain reimbursement for medicines. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | Regional | Sometimes | 114997831407 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 慢性
> 姑息治疗 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Regional | Sometimes | 115002049927 |
| Reimbursement applications for certain medicines through INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 风湿性
> 狼疮 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Regularly | 115029783188 |
| Ensuring reimbursement for specific medicines. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | Regional | Sometimes | 115029939063 |
| Equal treatment for women and men with breast cancer. Certain medications are reimbursed for women with breast cancer but not for men with the same condition. | 癌症
> 癌症（男性）：乳腺 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | Regional | Sometimes | 115031895194 |
| HPV [Human Papillomavirus] vaccination reimbursed for boys up to the age of 18. | 癌症
> 癌症：HPV | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | National | Sometimes | 115051943511 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 肾脏
> 肾脏疾病 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | Regional | Sometimes | 115055534359 |
| Request for medication reimbursement. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Regional | Sometimes | 115057073683 |
| Recommendation submitted to the CTG [Commissie Tegemoetkoming Geneesmiddelen – Drug Reimbursement Committee] via a completed questionnaire: reimbursement of Buccolam for individuals with epilepsy aged 18 years and over. | 神经系统
> 癫痫 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Regional | Sometimes | 115057861541 |
| [Advocate] for greater availability of well-maintained public restroom facilities, and for the establishment of a national Inflammatory Bowel Disease (IBD) awareness day. | 胃肠道
> IBD | 定价与可负担性倡导
> 参与宣传活动 | 100,000 | Regional | Sometimes | 115020038862 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 慢性
> 姑息治疗 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Sometimes | 115002049927 |
| [Advocate] for greater availability of well-maintained public restroom facilities, and for the establishment of a national Inflammatory Bowel Disease (IBD) awareness day. | 胃肠道
> IBD | 改善访问路径
> 促进公平获取药品/医疗保健 | 100,000 | Regional | Sometimes | 115020038862 |
| Reimbursement of PrEP [Pre-Exposure Prophylaxis] for community-based organisations. | 总体健康
> 性健康：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | Regional | Sometimes | 115046432045 |
| HPV [Human Papillomavirus] vaccination reimbursed for boys up to the age of 18. | 癌症
> 癌症：HPV | 改善访问路径
> 倡导更广泛的疫苗获取渠道 | 1,000 | National | Sometimes | 115051943511 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic [drug pricing] (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 稀有
> 罕见病：儿童/青少年 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | International | Sometimes | 115037392949 |
| Since the introduction of a patient advisory process for the CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Authority] procedure in early 2025, we have compiled a submission dossier on two occasions. | 稀有
> 囊性纤维化 | 循证患者意见
> 利用患者洞察来指导决策 | 1,000 | National | Sometimes | 115005093988 |
| [Patient] expert assessments in support of drug reimbursement decisions. | 神经退行性
> 痴呆症 | 循证患者意见
> 利用患者洞察来指导决策 | Do not know | Regional | Sometimes | 115043013133 |
| We represent the patient voice to mutual health insurance funds and within European consortia. | 医学研究
> 医学研究 | 循证患者意见
> 利用患者洞察来指导决策 | 100 | National | Rarely | 115057856231 |
| Input from the patient organisation on reimbursement dossiers for new medications (via an extensive questionnaire). | 癌症
> 癌症：肺 | 循证患者意见
> 开展调查/研究以生成数据 | 1,000 | Regional | Sometimes | 115039053506 |
| Since the introduction of a patient advisory process for the CTG [College Tarieven Gezondheidszorg - Healthcare Tariffs Authority] procedure in early 2025, we have compiled a submission dossier on two occasions. | 稀有
> 囊性纤维化 | 循证患者意见
> 将证据和洞察转化为政策建议 | 1,000 | National | Sometimes | 115005093988 |
| Regional discussion on the cardiovascular prevention plan, with outreach to municipalities and CPAS [Centre Public d'Action Sociale – Public Centre for Social Welfare]. | 心血管
> 心血管：大多数类型 | 诊断与药品配送
> 支持筛查和早期检测 | 100,000 | National | Regularly | 115042996911 |
| Working group on the new rare diseases plan, and various other working groups, committees, and similar bodies. | 稀有
> 罕见病：大多数类型 | 机构治理
> 确保在政府咨询机构中的代表性 | We do not communicate with patients directly | National | Regularly | 115005882213 |
| At RIZIV [Rijksinstituut voor Ziekte- en Invaliditeitsverzekering – National Institute for Health and Disability Insurance], among other bodies. | 癌症
> 癌症：血液 | 机构治理
> 确保在政府咨询机构中的代表性 | 1,000 | Regional | Regularly | 115010762888 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 血液
> 镰状细胞病 | 机构治理
> 确保在政府咨询机构中的代表性 | Do not know | National | Rarely | 115028443749 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic [drug pricing] (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 稀有
> 罕见病：儿童/青少年 | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | International | Sometimes | 115037392949 |
| Member of the steering committee for the national and regional plan. | HIV
> HIV与性健康 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | Regional | Sometimes | 115048515283 |
| On occasion, a subject-matter expert contributes through our overarching collaborative platform. | 风湿性
> 类风湿性关节炎 | 机构治理
> 在多利益相关方网络中高效协作 | 1,000 | Regional | Sometimes | 114998593281 |
| Working group on the new rare diseases plan, and various other working groups, committees, and similar bodies. | 稀有
> 罕见病：大多数类型 | 机构治理
> 在多利益相关方网络中高效协作 | We do not communicate with patients directly | National | Regularly | 115005882213 |
| I participate in the Observatoire des Maladies Chroniques [Observatory for Chronic Diseases] and in the work of the LUSS [Ligue des Usagers des Services de Santé – League of Health Service Users] (the umbrella body for patient associations), both of which address these subject areas. | 神经退行性
> 亨廷顿病 | 机构治理
> 在多利益相关方网络中高效协作 | 1,000 | National | Regularly | 115007525885 |
| We participate in stakeholder engagement sessions organised by Pharma.be and FAGG [Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten – Federal Agency for Medicines and Health Products]. | 血液
> 血液疾病：免疫性血小板减少症（ITP） | 机构治理
> 在多利益相关方网络中高效协作 | 100 | National | Sometimes | 115021567311 |
| Through the Luss [Ligue des Usagers des Services de Santé – League of Health Service Users], which brings together several patient associations and has a member sitting on the Drug Reimbursement Committee at the INAMI [Institut National d'Assurance Maladie-Invalidité – National Institute for Health and Disability Insurance]. | 血液
> 镰状细胞病 | 机构治理
> 在多利益相关方网络中高效协作 | Do not know | National | Rarely | 115028443749 |
| [Working with] LUSS [Ligue des usagers des services de santé – League of Healthcare Service Users]. | 神经系统
> 纤维肌痛 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | National | Sometimes | 115028484320 |
| Patient expert for rare diseases, pharmaceutical companies, and other associations. | 稀有
> 罕见病：肾脏 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | National | Regularly | 115028704257 |
| Our association is an active member of various associations and organisations that regularly participate in advisory committees on this topic (e.g. RaDiOrg, Rare Disorders Belgium & ERN [European Reference Network] Transplantchild). | 稀有
> 罕见病：儿童/青少年 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | International | Sometimes | 115037392949 |
| VPP [Vlaams Patiëntenplatform - Flemish Patients’ Platform] participates as a patient organisation in consultative platforms addressing key bottlenecks, such as reimbursement and temporary unavailability of medicines. Pricing policy is also covered within this remit. Through the ELZ [Eerstelijnszone – Primary Care Zone] P-Zon [Personen met een Zorg- en OndersteuningsNood - People with a Care and Support Need], we additionally ensure the patient voice is represented within the P-Zon cluster. | 肾脏
> 肾脏疾病 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | Regional | Sometimes | 115055534359 |
| Patient consultation at AstraZeneca. | 癌症
> 癌症（男性）：乳腺 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | Regional | Rarely | 115058978325 |
| Eligible to the EMA [European Medicines Agency] and invited to meetings and events, been part of regulatory evaluations. Member of EU HTA [Health Technology Assessment] stakeholder forum. | 神经退行性
> 亨廷顿病 | 机构治理
> 在多利益相关方网络中高效协作 | Do not know | International | Sometimes | 119075658991 |
| I am currently in the process of re-establishing the association, and once it is fully operational, that is the objective. | 皮肤
> 血管性水肿 | 机构治理
> 维持公益或慈善实体的正式地位 | 100 | National | Sometimes | 115043847394 |
| Equal treatment for women and men with breast cancer. | 癌症
> 癌症（男性）：乳腺 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100 | Regional | Sometimes | 115031895194 |
| Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies. | 慢性
> 姑息治疗 | 维护患者权益/提高生活质量
> 促进对生活质量的重视 | 1,000 | Regional | Sometimes | 115002049927 |
互动
行动与倡导
28 提及
